Skip to main content

Elizabeth Baker, Esq.

Pharmaceutical Policy Program Director

Elizabeth Baker, Esq., is the Pharmaceutical Policy Program Director for the Physicians Committee for Responsible Medicine, a nationwide organization of physicians and laypersons that promotes preventive medicine, especially good nutrition, and higher ethical standards in research. Ms. Baker works to modernize drug development to save human and animal lives by shifting nonclinical research from the use of animals to modern technologies that are more relevant to human biology.

Ms. Baker leads the Nonclinical Innovation and Patient Safety Initiative (NIPSI), a broad group of drug development stakeholders – including federal agencies, pharmaceutical companies, academics, technology companies, and patient, research and health organizations – in its work to improve the human relevance of nonclinical testing. Ms. Baker’s work facilitates advances in regulatory science to expedite the availability of safer, more effective, less expensive medicines that are developed with less animal testing.

Ms. Baker has authored numerous op eds, science blogs, regulatory petitions and manuscripts, including publication in Drug Discovery Today, ATLA, The Hill, STAT News, the Food and Drug Law Institute Policy Forum, the North Carolina Central University School of Law Biotechnology and Pharmaceutical Law Review and the Physicians Committee’s Good Science Digest regarding FDA policy and innovative human-based science for drug development.

Ms. Baker is a member of the California Bar Association, the American Society for Cellular and Computational Toxicology, the Society of Toxicology and the American Association for Advancement of Science.

Ms. Baker graduated cum laude from California Western School of Law, where she earned honors in the health law and policy concentration and received American Jurisprudence awards for her work in FDA law, bioethics, animal law, and legal research and writing. Ms. Baker received her bachelor’s degree in psychology from the University of San Diego.

Read more about Ms. Baker’s latest work:

Physicians Committee Input at FDA Predictive Toxicology Roadmap Stakeholder Meeting

Burt, T., et al. Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development. Alternatives to Laboratory Animals. December 6, 2018.

Baker E., et al. Advancing nonclinical innovation and safety in pharmaceutical testing. Drug Discovery Today. November 20, 2018.

Baker E. FDA’s new predictive toxicology roadmap will improve human safety. The Hill. December 11, 2017.  

Baker, E. Preclinical innovation and patient safety: Supporting human-based science through advances in law, policy, education and training. Presented at: Keystone Symposium on Molecular and Cellular Biology; April 12, 2018; Big Sky, MT.  

Baker, E. The preclinical innovation and patient safety initiative: Recommendations for modernizing preclinical testing. Poster presented at: Society on Toxicology Annual Meeting; March 12,2018; San Antonio, TX.